Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | UBE2M | P61081 | 1/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3290805 | 0.93 | KDM4E (0.47) | PRKAA2P2RX1KDM4EGAASCN9A | |
| SCHEMBL3291608 | 0.91 | SMO (0.46) | SMN1; SMN2MAPTHTTPRKAA2ALDH1A1 | |
| SCHEMBL3295277 | 0.90 | P2RX1 (0.47) | PRKAA2P2RX1KDM4EGAASCN9A | |
| SCHEMBL5145537 | 0.90 | SMN1; SMN2 (0.52) | SMN1; SMN2MAPTHTTALDH1A1KDM4E | |
| SCHEMBL3294697 | 0.84 | SMO (0.45) | MAPTPRKAA2P2RX1KDM4EGAA | |
| SCHEMBL3289823 | 0.84 | KDM4E (0.46) | PRKAA2P2RX1KDM4EGAAP2RY12 | |
| SCHEMBL3289542 | 0.84 | MAPT (0.48) | SMN1; SMN2MAPTHTTPRKAA2ALDH1A1 | |
| SCHEMBL3290189 | 0.84 | SMN1; SMN2 (0.51) | SMN1; SMN2MAPTHTTALDH1A1LMNA | |
| SCHEMBL3290350 | 0.84 | KDM4E (0.50) | SMN1; SMN2MAPTPRKAA2ALDH1A1LMNA | |
| SCHEMBL3313226 | 0.83 | PRKAA2 (0.46) | PRKAA2ALDH1A1KDM4EGAASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723358-B2 | Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems | MERCK PATENT GMBH (DE) | 2010-05-25 | — | — | US | disclosed |
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | MERCK PATENT GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | GPR119, FABP4, LIPC | SMN1; SMN2 4852/4885MAPT 4285/4885HTT 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.